11h
Zacks Investment Research on MSNVertex Up 25% YTD: Should You Buy, Sell or Hold the Stock?Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX ...
Most of the focus in generative AI has been on text-based interfaces used to generate text, images, and more. The next wave ...
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...
In a regulatory filing, Vertex Pharmaceuticals (VRTX) chief scientific officer David Altshuler disclosed the sale of 3,231 common shares of the ...
Goldman Sachs analyst expects positive updates from Vertex's first Investor Day as a public company on March 19, reiterates ...
To address the decline in daily active users (“DAU”) because of its algorithm change, Google (GOOG, GOOGL) is expanding its ...
The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...
10d
MoneyWeek on MSNVertex Pharmaceuticals is an uncommon opportunity in rare diseasesVertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...
Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...
Google announced to integrate Chirp 3, the voice-based and HD text-to-speech models to its Vertex AI development platform ...
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results